Lisata Therapeutics (NASDAQ:LSTA) Posts Quarterly Earnings Results

Lisata Therapeutics (NASDAQ:LSTA) issued its earnings results on Thursday. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.21, Zacks reports. The company had revenue of $1.00 million during the quarter.

Lisata Therapeutics Price Performance

LSTA stock traded down $0.04 during midday trading on Friday, hitting $2.36. The stock had a trading volume of 6,162 shares, compared to its average volume of 57,017. The company’s 50-day moving average price is $2.96 and its 200 day moving average price is $2.92. Lisata Therapeutics has a 12-month low of $2.19 and a 12-month high of $4.20. The firm has a market cap of $19.81 million, a PE ratio of -0.94 and a beta of 1.14.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.